TuisIMM • ASX
add
Immutep Ltd
Vorige sluiting
$0,32
Dagwisseling
$0,32 - $0,33
Jaarwisseling
$0,23 - $0,46
Markkapitalisasie
487,96 m AUD
Gemiddelde volume
3,88 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
ASX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (AUD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 865,57 k | -4,89% |
Bedryfskoste | 2,03 m | -10,92% |
Netto inkomste | -10,74 m | -11,49% |
Netto winsgrens | -1,24 k | -17,23% |
Wins per aandeel | — | — |
EBITDA | -11,21 m | -17,52% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (AUD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 181,88 m | 47,37% |
Totale bates | 201,58 m | 36,71% |
Totale aanspreeklikheid | 12,06 m | 9,82% |
Totale ekwiteit | 189,52 m | — |
Uitstaande aandele | 1,45 mjd | — |
Prys om te bespreek | 2,46 | — |
Opbrengs op bates | -14,53% | — |
Opbrengs op kapitaal | -15,32% | — |
Kontantvloei
Netto kontantverandering
| (AUD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -10,74 m | -11,49% |
Kontant van bedrywe | -8,19 m | 30,16% |
Kontant van beleggings | -10,30 m | -87 445,92% |
Kontant van finansiering | 47,81 m | 25,58% |
Netto kontantverandering | 29,03 m | 5,47% |
Beskikbare kontantvloei | -6,10 m | -44,31% |
Meer oor
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
HUB
Gestig
2001
Webwerf
Werknemers
19
